Ona Therapeutics Appoints Key Leaders to Propel First-in-Class Antibody-Drug Conjugates into Clinical Trials

Ona Therapeutics Strengthens Leadership Team

Ona Therapeutics, a pioneering biotech firm based in Barcelona, has taken significant steps forward in its mission to develop groundbreaking antibody-drug conjugates (ADCs) targeting various types of cancer. Recently, the company made key leadership appointments, aimed at accelerating its growth and advancing its innovative therapies into clinical trials.

Key Leadership Appointments

Dr. Aleix Prat, a renowned expert in drug and biomarker development, has been appointed as the Chair of the Advisory Board. His extensive experience in precision oncology and impressive track record in cancer research will play a critical role in guiding Ona's strategic vision. Alongside him, Dr. Jutta Amersdorffer has been named Chief Medical Officer. With a wealth of experience in translational medicine and innovative biologics, she adds valuable expertise to Ona's leadership team. Lastly, Stéphane Durant des Aulnois steps in as Chief Financial Officer, bringing over two decades of finance and healthcare experience to the table.

Focus on Innovative ADCs

Ona is on a path to develop first-in-class ADCs that specifically target solid tumors, particularly those that are hard to treat and often resistant to standard therapies. The company's lead ADC, ONA-255, is currently undergoing preclinical studies and has shown promise in treating breast, gastric, and other solid tumors. They aim to progress to clinical development by the end of 2025. Additionally, ONA-389, a second ADC targeting advanced microsatellite stable colon and liver cancers, is planned for IND-enabling studies in late 2025.

The company's strategy is based on understanding the unique biology of treatment-resistant advanced cancer. By analyzing difficult-to-obtain patient biopsies, Ona seeks to identify novel therapeutic targets that can lead to the development of effective therapies for patients with limited options. This approach, combined with the expertise of its leadership team, positions the company to redefine the treatment landscape for aggressive cancer forms.

Expertise and Collaborative Approach

Dr. Aleix Prat is not only leading the Advisory Board but also collaborating with Ona's advisors to validate critical targets for their ADC therapies. Through partnerships with top academicians and clinical research experts, Ona plans to leverage insights into the biological foundations of illness. Dr. Prat, Professor of Medicine at the University of Barcelona and Director of the Clínic Barcelona Comprehensive Cancer Center, comes with numerous accolades in the field, including over 300 publications and multiple leadership roles in oncology initiatives.

In her role, Dr. Jutta Amersdorffer will oversee the clinical and medical development processes at Ona, ensuring that the company remains compliant while advancing its pipeline. Her robust background in pharmacovigilance for innovative therapies further fortifies Ona's capability to bring new ADCs to market successfully.

Stéphane Durant des Aulnois's finance acumen, honed through previous roles in companies like Ipsen and Lysogene, enhances Ona’s capabilities in business development and investor relations, critical for supporting the company’s growth trajectory.